Small molecule · Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1)
Phase 1Most advanced trial
1Registered trials
What is SNV1521?
SNV1521 is an orally bioavailable inhibitor of PARP1, a nuclear enzyme that repairs damaged DNA. By blocking PARP1 activity, it prevents base excision repair, leading to accumulation of DNA strand breaks and apoptosis. It is being studied in combination with the RAS inhibitor daraxonrasib in pancreatic cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Small molecule
Targets
poly(ADP-ribose) polymerase 1 (PARP1)
Mechanism
Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1)
Pathways
base excision repair, DNA single-strand break repair, double-strand break repair, apoptosis
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.